AdAlta nears FDA advice as EW-001 reaches Australian manufacturing stage

FDA advice becomes the next test for EW-001

AdAlta Limited (ASX:1AD) is approaching a regulatory checkpoint that could shape the next stage of its mesothelioma CAR-T program. The US Food and Drug Administration has accepted a pre-IND meeting request for EW-001, with the discussion scheduled for 3 November US time, or 4 November in Australia.

The meeting will examine the proposed manufacturing approach, remaining laboratory and animal studies, and the design of a planned Australian Phase 1 trial. The FDA typically issues written minutes two to four weeks after such a meeting, giving AdAlta a more precise view of what may still be required before clinical trials can proceed under US oversight. The company had already reported its FDA briefing pack submission, which addressed those same development questions.

Melbourne manufacturing moves from plan to execution

AdAlta and Shanghai Cell Therapy Group formally approved the transfer of EW-001’s manufacturing process and testing methods to Cell Therapies in Melbourne. First Australian manufacturing runs remain targeted for the second half of calendar 2026.

That step matters because CAR-T products are made from each patient’s own immune cells, making manufacturing speed, consistency and cost central to development. AdAlta says producing EW-001 in Australia to FDA standards would reduce supply and regulatory risks and make the program more attractive to potential pharmaceutical partners. The manufacturing transfer follows the previously reported Melbourne manufacturing transfer, but neither the Australian runs nor the Phase 1 trial has yet been completed.

Early Chinese data offers a clinical signal, not a conclusion

The company also highlighted follow-up from small investigator-initiated studies in China. The first patient to achieve a complete response has passed two years without cancer recurrence after a single dose of EW-001. Three of 10 patients treated at higher doses had survived at least 12 months in the latest cited update, while two patients remained under study as at 5 October.

Those findings are potentially important in advanced mesothelioma, where complete tumour clearance is uncommon, but AdAlta acknowledges that the studies involve small patient numbers and are uncontrolled. Hainan regulators have authorised EW-001 for special access at Ruijin Hospital, an approval that is distinct from full commercial marketing approval and had not yet resulted in treatment under the scheme as at 5 October. The special-access decision followed the Hainan special-access approval and is expected to provide additional real-world data.

Funding improves, but the runway remains narrow

AdAlta received A$0.23 million from the R&D Tax Incentive during the quarter and expects more than A$1 million in additional inflows during the December quarter after securing an Advance Overseas Finding for qualifying EW-001 work conducted in China. The earlier refund and expected top-up provide non-dilutive support, but the latter remains an anticipated cash inflow rather than money already received.

Net operating cash use was A$0.58 million for the September quarter, leaving A$0.65 million in cash and cash equivalents at 30 September. On the quarter’s operating burn, the Appendix 4C reports only 1.1 quarters of funding. AdAlta says it is pursuing third-party financing for EW-001 and options to monetise AD-214 and WD-34, but also states that the probability of success depends on progress during the December quarter.

The immediate sequence is therefore clear: FDA minutes, proof of Australian manufacturing, receipt of the expected tax incentive and progress on outside financing. The science may be gaining credibility, but the company’s ability to reach the next clinical stage will also depend on whether those funding events arrive before the current cash buffer is exhausted.